Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Agenus Inc 3 FORBES ROAD LEXINGTON MA 02421 USA

P: 781-674-4400 F: 781-674-4200

Description:

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 502,741
Shares Outstanding, K 137,361
Annual Sales, $ 36,780 K
Annual Net Income, $ -159,690 K
Last Quarter Sales, $ 19,940 K
Last Quarter Net Income, $ -45,470 K
60-Month Beta 2.29
% of Insider Shareholders 5.20%
% of Institutional Shareholders 35.73%
Float, K 130,218
% Float 94.80%

Growth:

1-Year Return 3.39%
3-Year Return -18.85%
5-Year Return -29.62%
5-Year Revenue Growth 1,105.90%
5-Year Earnings Growth -28.57%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 03/12/20
Earnings Per Share ttm -0.99
EPS Growth vs. Prev Qtr 13.16%
EPS Growth vs. Prev Year -13.79%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-6 on 10/03/11

AGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -1.80
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -67.84%
Profit Margin % -434.18
Net Margin % -651.56
Debt/Equity N/A
Price/Sales 3.92
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.49
Interest Coverage -5.41
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar